Multiple Myeloma Coverage From Every Angle
Advertisement
Advertisement

Recent News

ASH 2017: CAR T-Cell Therapy in Heavily Pretreated Patients With Myeloma
MCRI Provides Funding for Novel Multiple Myeloma Research
Limiting Antigen Escape in Patients With Relapsed Multiple Myeloma
Dose-Escalation Study of CLR 131 in Relapsed or Refractory Multiple Myeloma
Potential of Diuretic Amiloride in Multiple Myeloma
Role of NGLY1 in Multiple Myeloma Treatment Resistance
AORTIC 2017: Patient Access to Hematopoietic Stem Cell Transplantation in Sub-Saharan Africa
FDA Approves Letermovir to Prevent Cytomegalovirus Infection in Patients Who Receive HSCT
Effect of UTX Loss in Multiple Myeloma
Once-Weekly vs. Twice-Weekly Carfilzomib in Relapsed or Refractory Myeloma
2017 Palliative Care Symposium: Sexual Dysfunction Intervention for HCT Survivors
Long-Term Impact of ASCT in Patients With Multiple Myeloma
2017 NCCN Hematologic Malignancies Congress: Managing Common Complications of Myeloma and Its Treatment
2017 NCCN Hematologic Malignancies Congress: Managing Newly Diagnosed Transplant-Eligible Myeloma Patients
2017 NCCN Hematologic Malignancies Congress: Treatment Update on Relapsed or Refractory Multiple Myeloma
Bortezomib Plus Hsp90 Inhibitor in Relapsed or Refractory Multiple Myeloma
Comparison of Two Lenalidomide-Based Triplets in Newly Diagnosed Multiple Myeloma
Combination Treatment in Newly Diagnosed Patients With Multiple Myeloma
New Drug Combination in Newly Diagnosed Multiple Myeloma
Ixazomib-Based Triplet Therapy for Newly Diagnosed Multiple Myeloma
Comparison of Two Induction Therapies for Newly Diagnosed Multiple Myeloma
ESMO 2017: Infusion-Related Reactions in Myeloma Patients Treated With Daratumumab
Anti-BCMA CAR T-Cell Therapy for Multiple Myeloma
Elotuzumab Combination Therapy for Relapsed or Refractory Myeloma
Isatuximab Combination Therapy for Relapsed or Refractory Multiple Myeloma
Daratumumab Triplet Approved for Relapsed or Refractory Myeloma
CAR-T Therapy for Refractory or Relapsed Multiple Myeloma
Maintenance Therapy With Ixazomib Without Stem Cell Transplant in Patients With Myeloma
FDA Statement on Safety Concerns Related to Investigational Use of Pembrolizumab in Multiple Myeloma
Denosumab vs. Zoledronic Acid in Myeloma-Related Bone Disease